Table 2.
Achievability of low disease activity state and remission definitions in cSLE patients
| Target attainment during follow-up | Number of patients (%) (n = 430) | Number of visits (%) (n = 4738) | Time to target attainment, median (IQR), months | Percentage of time in target per patient, median (IQR) | Length of time in target, median (IQR), months |
|---|---|---|---|---|---|
| Low disease activity | |||||
| LLDAS | 286 (67) | 918 (19) | 18.0 (8.5, 30.8) | 22.9 (12.8, 36.8) | 10.1 (6.0, 20.1) |
| LA | 314 (73) | 1368 (29) | 14.6 (7.4, 26.8) | 31.4 (15.9, 51.5) | 13.7 (7.0, 27.6) |
| Toronto-LDA | 136 (32) | 393 (8) | 17.0 (2.9, 37.7) | 18.6 (9.2, 42.5) | 9.9 (4.4, 22.1) |
| Remission definitions | |||||
| On-treatment (SLEDAI-defined) | 261 (61) | 848 (18) | 16.8 (8.5, 29.9) | 27.9 (14.8, 45.6) | 12.1 (6.0, 22.8) |
| On-treatment (BILAG-defined) | 182 (42) | 469 (10) | 20.7 (11, 38.0) | 18.8 (10.3, 33.0) | 10.3 (4.8, 18.2) |
| Off-treatment (SLEDAI-defined)a | 134 (31) | 351 (7) | 21.5 (5.5, 39.5) | 15.4 (7.7, 40.8) | 9.6 (4.5, 20.0) |
| Off-treatment (BILAG-defined)a | 90 (21) | 200 (4) | 24.3 (8.5, 41.8) | 14.8 (6.7, 25.5) | 8.7 (3.2, 16.1) |
a
For those achieving remission off-treatment, hydroxychloroquine was still allowable and was prescribed during 37.6% of all visits when in SLEDAI-defined remission off-treatment, and 42.5% of all visits when in BILAG-defined remission off-treatment. BILAG: definition of remission based upon the BILAG score; cSLE: childhood-onset SLE; IQR: interquartile range; LA: low activity; LDA: low disease activity; LLDAS: lupus low disease activity state; SLEDAI: definition of remission based upon the SLEDAI.